|
Onco-Innovations Limited, a Canadian-based company dedicated to cancer research, treatment, and specializing in oncology, announced the appointment of Dr. Islam Mohamed as chair of its Scientific and Clinical Advisory Board. This appointment reflects the company's commitment to scientific excellence and its mission to accelerate the development of innovative oncology solutions through expert-led translational research.
Dr. Islam Mohamed is an experienced radiation oncologist, clinical researcher, and biotechnology advisor who has spent over two decades operating at the intersection of oncology and innovation. After earning an Honours BSc in Genetics, he pursued a career in Medicine, completing his specialty training in Radiation Oncology in 2000. At BC Cancer, he has built a distinguished clinical career focused on lung, breast, skin cancers, and sarcoma, and is recognized for his expertise in stereotactic radiation delivery.
Dr. Mohamed has led numerous clinical trials at both local and provincial levels, contributing to advances in the treatment of breast, lung, and oligometastatic cancers. He has also served on research ethics boards and national clinical trial committees, shaping standards of care and clinical research strategy in Canada.
Complementing his clinical leadership, Dr. Mohamed brings deep insight into the health technology ecosystem. He advises and invests in emerging Canadian biotech ventures, including Linax Technologies, IllumiSonics, and Asep Medical, with a focus on companies developing transformative diagnostics, therapeutics, and platform technologies. His combined experience as a clinician, researcher, and entrepreneur positions him as a strategic asset in evaluating innovation, guiding translational research, and driving value creation.
The Scientific and Clinical Advisory Board plays a critical role in supporting Onco-Innovations' research and development (R&D) priorities. Its mandate is to provide strategic guidance on research and development initiatives, facilitate clinical and scientific collaboration among partners, and support the mobilization of knowledge and generation of independent scientific insights to guide decision-making.
"We are thrilled to welcome Dr. Mohamed as chair of our Scientific and Clinical Advisory Board. His deep clinical insight, research leadership, and strategic involvement in biotech innovation will be instrumental as we advance our oncology pipeline and translational research initiatives," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
|